Literature DB >> 29897282

Divergent effects of AKI to CKD models on inflammation and fibrosis.

L M Black1, J M Lever1, A M Traylor1, B Chen1, Z Yang1, S K Esman1, Y Jiang1, G R Cutter2, R Boddu1, J F George1,3, A Agarwal1,4.   

Abstract

Chronic kidney disease (CKD) is a condition with significant morbidity and mortality that affects 15% of adults in the United States. One cause of CKD is acute kidney injury (AKI), which commonly occurs secondary to sepsis, ischemic events, and drug-induced nephrotoxicity. Unilateral ischemia-reperfusion injury (UIRI) without contralateral nephrectomy (CLN) and repeated low-dose cisplatin (RLDC) models of AKI to CKD demonstrate responses characteristic of the transition; however, previous studies have not effectively compared the pathogenesis. We demonstrate both models instigate renal dysfunction, inflammatory cytokine responses, and fibrosis. However, the models exhibit differences in urinary excretory function, inflammatory cell infiltration, and degree of fibrotic response. UIRI without CLN demonstrated worsening perfusion and function, measured with 99mTc-mercaptoacetyltriglycine-3 imaging, and physiologic compensation in the contralateral kidney. Furthermore, UIRI without CLN elicited a robust inflammatory response that was characterized by a prolonged polymorphonuclear cell and natural killer cell infiltrate and an early expansion of kidney resident macrophages, followed by T-cell infiltration. Symmetrical diminished function occurred in RLDC kidneys and progressively worsened until day 17 of the study. Surprisingly, RLDC mice demonstrated a decrease in inflammatory cell numbers relative to controls. However, RLDC kidneys expressed increased levels of kidney injury molecule-1 (KIM-1), high mobility group box-1 ( HMGB1), and colony stimulating factor-1 ( CSF-1), which likely recruits inflammatory cells in response to injury. These data emphasize how the divergent etiologies of AKI to CKD models affect the kidney microenvironment and outcomes. This study provides support for subtyping AKI by etiology in human studies, aiding in the elucidation of injury-specific pathophysiologic mechanisms of the AKI to CKD transition.

Entities:  

Keywords:  chronic kidney disease; cisplatin; fibrosis; glomerular filtration rate; inflammation; ischemia-reperfusion

Mesh:

Year:  2018        PMID: 29897282      PMCID: PMC6230746          DOI: 10.1152/ajprenal.00179.2018

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  60 in total

1.  Acute unilateral ischemic renal injury induces progressive renal inflammation, lipid accumulation, histone modification, and "end-stage" kidney disease.

Authors:  Richard A Zager; Ali C M Johnson; Kirsten Becker
Journal:  Am J Physiol Renal Physiol       Date:  2011-09-14

2.  Transcutaneous measurement of glomerular filtration rate in small rodents: through the skin for the win?

Authors:  Stacey J Ellery; Xiaochu Cai; David D Walker; Hayley Dickinson; Michelle M Kett
Journal:  Nephrology (Carlton)       Date:  2015-03       Impact factor: 2.506

3.  GM-CSF Promotes Macrophage Alternative Activation after Renal Ischemia/Reperfusion Injury.

Authors:  Sarah C Huen; Larry Huynh; Arnaud Marlier; Yashang Lee; Gilbert W Moeckel; Lloyd G Cantley
Journal:  J Am Soc Nephrol       Date:  2014-11-11       Impact factor: 10.121

Review 4.  Mechanisms of Renal Fibrosis.

Authors:  Benjamin D Humphreys
Journal:  Annu Rev Physiol       Date:  2017-10-25       Impact factor: 19.318

5.  Chemotherapy-induced myelotoxicity and incidence of lung metastasis in an animal model.

Authors:  Jin-Young Son; Jang-Woo Shin; Jing-Hua Wang; Hye-Jung Park; Hyeong-Geug Kim; Hanumantha Rao Balaji Raghavendran; Chang-Gue Son
Journal:  Hum Exp Toxicol       Date:  2010-07-14       Impact factor: 2.903

6.  The chemokine receptors CCR2 and CX3CR1 mediate monocyte/macrophage trafficking in kidney ischemia-reperfusion injury.

Authors:  Li Li; Liping Huang; Sun-Sang J Sung; Amy L Vergis; Diane L Rosin; C Edward Rose; Peter I Lobo; Mark D Okusa
Journal:  Kidney Int       Date:  2008-10-08       Impact factor: 10.612

7.  Subclinical kidney injury induced by repeated cisplatin administration results in progressive chronic kidney disease.

Authors:  Cierra N Sharp; Mark A Doll; Judit Megyesi; Gabrielle B Oropilla; Levi J Beverly; Leah J Siskind
Journal:  Am J Physiol Renal Physiol       Date:  2018-01-31

8.  Dosing regimen of granulocyte-macrophage colony-stimulating factor to support dose-intensive chemotherapy.

Authors:  J A Neidhart; A Mangalik; C A Stidley; S L Tebich; L E Sarmiento; J E Pfile; D H Oette; F B Oldham
Journal:  J Clin Oncol       Date:  1992-09       Impact factor: 44.544

Review 9.  Subcellular targets of cisplatin cytotoxicity: an integrated view.

Authors:  Sandra M Sancho-Martínez; Laura Prieto-García; Marta Prieto; José M López-Novoa; Francisco J López-Hernández
Journal:  Pharmacol Ther       Date:  2012-07-14       Impact factor: 12.310

10.  Metformin Protects Against Cisplatin-Induced Tubular Cell Apoptosis and Acute Kidney Injury via AMPKα-regulated Autophagy Induction.

Authors:  Jianzhong Li; Yuan Gui; Jiafa Ren; Xin Liu; Ye Feng; Zhifeng Zeng; Weichun He; Junwei Yang; Chunsun Dai
Journal:  Sci Rep       Date:  2016-04-07       Impact factor: 4.379

View more
  34 in total

1.  Glycolysis inhibitors suppress renal interstitial fibrosis via divergent effects on fibroblasts and tubular cells.

Authors:  Qingqing Wei; Jennifer Su; Guie Dong; Ming Zhang; Yuqing Huo; Zheng Dong
Journal:  Am J Physiol Renal Physiol       Date:  2019-04-10

2.  Single-Nucleus Transcriptional Profiling of Chronic Kidney Disease after Cisplatin Nephrotoxicity.

Authors:  Zhengwei Ma; Xiaoru Hu; Han-Fei Ding; Ming Zhang; Yuqing Huo; Zheng Dong
Journal:  Am J Pathol       Date:  2022-01-31       Impact factor: 4.307

3.  C57BL/6 mice require a higher dose of cisplatin to induce renal fibrosis and CCL2 correlates with cisplatin-induced kidney injury.

Authors:  Sophia M Sears; Cierra N Sharp; Austin Krueger; Gabrielle B Oropilla; Douglas Saforo; Mark A Doll; Judit Megyesi; Levi J Beverly; Leah J Siskind
Journal:  Am J Physiol Renal Physiol       Date:  2020-08-24

4.  Evaluation of cisplatin-induced injury in human kidney organoids.

Authors:  Jenny L M Digby; Thitinee Vanichapol; Aneta Przepiorski; Alan J Davidson; Veronika Sander
Journal:  Am J Physiol Renal Physiol       Date:  2020-03-09

5.  Capillary rarefaction is more closely associated with CKD progression after cisplatin, rhabdomyolysis, and ischemia-reperfusion-induced AKI than renal fibrosis.

Authors:  Anna Menshikh; Lauren Scarfe; Rachel Delgado; Charlene Finney; Yuantee Zhu; Haichun Yang; Mark P de Caestecker
Journal:  Am J Physiol Renal Physiol       Date:  2019-09-11

6.  Molecular targeting of renal inflammation using drug delivery technology to inhibit NF-κB improves renal recovery in chronic kidney disease.

Authors:  Alejandro R Chade; Maxx L Williams; Jason E Engel; Erika Williams; Gene L Bidwell
Journal:  Am J Physiol Renal Physiol       Date:  2020-06-15

7.  Pretreatment of carprofen impaired initiation of inflammatory- and overlapping resolution response and promoted cardiorenal syndrome in heart failure.

Authors:  Veena Krishnan; David Booker; Gabrielle Cunningham; Jeevan Kumar Jadapalli; Vasundhara Kain; Amanda B Pullen; Ganesh V Halade
Journal:  Life Sci       Date:  2018-12-28       Impact factor: 5.037

Review 8.  UAB-UCSD O'Brien Center for Acute Kidney Injury Research.

Authors:  Lisa M Curtis; James George; Volker Vallon; Stephen Barnes; Victor Darley-Usmar; Sucheta Vaingankar; Gary R Cutter; Orlando M Gutierrez; Michael Seifert; Joachim H Ix; Ravindra L Mehta; Paul W Sanders; Anupam Agarwal
Journal:  Am J Physiol Renal Physiol       Date:  2021-03-29

Review 9.  Renal Inflammation and Fibrosis: A Double-edged Sword.

Authors:  Laurence M Black; Jeremie M Lever; Anupam Agarwal
Journal:  J Histochem Cytochem       Date:  2019-05-22       Impact factor: 2.479

10.  Separated parabiont reveals the fate and lifespan of peripheral-derived immune cells in normal and ischaemia-induced injured kidneys.

Authors:  Xuan Deng; Cheng Zhou; Ruichun Liao; Yi Guo; Yuxi Wang; Guoli Li; Jianliang Wu; Huzi Xu; Zhizhi Hu; Guangchang Pei; Wenhui Liao; Ying Yao; Qian Yang; Rui Zeng; Gang Xu
Journal:  Open Biol       Date:  2021-06-09       Impact factor: 6.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.